Mitsubishi UFJ Asset Management Co. Ltd. Raises Stake in Pfizer Inc. (NYSE:PFE)

Mitsubishi UFJ Asset Management Co. Ltd. raised its holdings in shares of Pfizer Inc. (NYSE:PFE) by 8.1% during the fourth quarter, Holdings Channel reports. The fund owned 9,013,007 shares of the biopharmaceutical company’s stock after buying an additional 674,556 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Pfizer were worth $239,656,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Retirement Wealth Solutions LLC purchased a new position in Pfizer in the 4th quarter worth $26,000. Rialto Wealth Management LLC bought a new stake in shares of Pfizer in the 4th quarter valued at about $26,000. Kohmann Bosshard Financial Services LLC purchased a new stake in Pfizer during the 4th quarter valued at about $28,000. Noble Wealth Management PBC bought a new position in Pfizer during the 4th quarter worth approximately $31,000. Finally, Curio Wealth LLC purchased a new position in Pfizer in the 4th quarter worth approximately $32,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

PFE has been the subject of several analyst reports. UBS Group dropped their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Truist Financial cut their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. Bank of America reaffirmed a “neutral” rating and set a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Finally, Hsbc Global Res raised Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $31.92.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.06% of the stock is owned by corporate insiders.

Pfizer Stock Down 1.4 %

Shares of Pfizer stock opened at $25.19 on Thursday. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The firm has a market cap of $142.88 billion, a price-to-earnings ratio of 17.87, a PEG ratio of 0.64 and a beta of 0.61. The company has a 50-day moving average of $26.12 and a 200 day moving average of $26.98. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same quarter in the prior year, the company earned $0.10 earnings per share. The business’s revenue was up 24.7% compared to the same quarter last year. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.